160 related articles for article (PubMed ID: 32132075)
1. Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
Watanabe H; Hayashi T; Komori K; Hara K; Maezawa Y; Kano K; Shimoda Y; Fujikawa H; Aoyama T; Yamada T; Yamamoto N; Cho H; Ito H; Shiozawa M; Yukawa N; Morinaga S; Yoshikawa T; Rino Y; Masuda M; Ogata T; Oshima T
Anticancer Res; 2020 Mar; 40(3):1683-1690. PubMed ID: 32132075
[TBL] [Abstract][Full Text] [Related]
2. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
3. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
Okubo K; Arigami T; Matsushita D; Tanaka T; Tsuruda Y; Noda M; Sasaki K; Mori S; Kurahara H; Ohtsuka T
Oncology; 2021; 99(6):380-388. PubMed ID: 33677434
[TBL] [Abstract][Full Text] [Related]
5. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
6. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
7. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
10. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
[TBL] [Abstract][Full Text] [Related]
11. Tumor size ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
Tsutsuyama M; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
World J Surg; 2020 Jan; 44(1):194-201. PubMed ID: 31552460
[TBL] [Abstract][Full Text] [Related]
12. [Examination of continuity of S-1 adjuvant chemotherapy for gastric cancer patients after gastrectomy].
Kawabata R; Imamura H; Kishimoto T; Anami S; Yasui Y; Fujino M; Fujii C; Sumida R; Furukawa H
Gan To Kagaku Ryoho; 2011 May; 38(5):793-5. PubMed ID: 21566439
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
[TBL] [Abstract][Full Text] [Related]
14. Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
Tanaka H; Tamura T; Toyokawa T; Muguruma K; Miki Y; Kubo N; Sakurai K; Hirakawa K; Ohira M
Anticancer Res; 2018 Jun; 38(6):3745-3751. PubMed ID: 29848737
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
[TBL] [Abstract][Full Text] [Related]
16. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
17. [Preoperative C-reactive protein predicts recurrence after curative resection in advanced gastric cancer patients receiving postoperative adjuvant chemotherapy using S-1].
Shimizu T; Ishizuka M; Sakuraoka Y; Shiraki T; Abe A; Mori S; Iso Y; Takagi K; Aoki T; Kubota K
Nihon Shokakibyo Gakkai Zasshi; 2020; 117(2):150-156. PubMed ID: 32037360
[TBL] [Abstract][Full Text] [Related]
18. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.
Nishibeppu K; Komatsu S; Ichikawa D; Imamura T; Kosuga T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Otsuji E
BMC Cancer; 2018 Jan; 18(1):108. PubMed ID: 29382310
[TBL] [Abstract][Full Text] [Related]
19. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
[TBL] [Abstract][Full Text] [Related]
20. Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Jun; 14(2):150-4. PubMed ID: 21327443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
